Floatz logo

sct200

Advanced Squamous Non-small Cell Lung Cancer

Sinocelltech Ltd.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

55 Active assets in the Advanced Squamous Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BBB
Pembrolizumab
Shanghai Henlius Biotech
Phase 3BB
Serplulimab
Shanghai Henlius Biotech
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BB
Docetaxel
Shanghai Henlius Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

sct200 is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
52 / 100
View asset →
esophageal squamous cell carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →